Recipients of Allogeneic Stem Cell TransplantationPhase 2NCT06793410
Vaccination Against Human Papillomavirus (HPV) After Allogeneic Stem Cell Transplantation
A Phase 2 study testing Early start post-transplant vaccination with Gardasil 9® and Late post-transplant vaccination with Gardasil 9® in people with Recipients of Allogeneic Stem Cell Transplantation and HPV (Human Papillomavirus)-Associated, run by Vastra Gotaland Region at 5 sites in Sweden.
Trial summary
Patients who undergo allogeneic stem cell transplantation lose previously acquired immunity and are routinely revaccinated against many infectious diseases. For several reasons, these patients have a long-term immune deficiency due to the transplant itself (lack of immune reconstitution) and due to possible… Read more about this study
- Who is it for?
- Ages 18 to 45 years
- Conditions the study is for
- Recipients of Allogeneic Stem Cell Transplantation, HPV (Human Papillomavirus)-Associated, Acute Myeloid Leukaemia
- What is being tested?
- Early start post-transplant vaccination with Gardasil 9® and Late post-transplant vaccination with Gardasil 9®
- Type of treatment
- Vaccines
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 100 participants
- Where
- 5 sitesSweden
- Study dates
- 12 May 2025to 31 Oct 2029
- Phase
- Phase 2
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 45 years
- All sexes
- No healthy volunteers
- Adult
Who may be able to join
- Recipient of AlloSCT from related or unrelated donor.
- Adults (men and women) ≥18 years up to and including 45 years of age for vaccination.
- Patients can be included regardless of prior HPV vaccination prior to transplantation
Who cannot join
- Severe thrombocytopenia (under 50 x 10^9) not allowing intramuscular injection
- Severe acute GvHD grade III-IV.
- Extensive chronic GvHD requiring treatment with prednisone doses above 0.7 mg/kg/day plus at least two other systemic treatments against GvHD (for example ruxolitinib or photopheresis).
- Prednisone doses above 1mg/kg/day at study start.
- Treatment with rituximab 6 months before start of vaccination. Doses given later (unusual) do not require exclusion.
- Treatment within 3 months before start of vaccination with iv or sc immunoglobulin.
Show all 9Show fewer
- Pregnancy, pregnancy desire or active pregnancy planning during time vaccine is given and up to three months after last vaccine dose.
- Treatment with blood thinning medication contraindicating intramuscular injection
- Allergy against Gardasil 9
Trial locations and contacts
5 sites in 1 country. Contact the study team or a site near you to ask about taking part.
5 sites in 1 country
Sweden5 sites, 5 recruiting
- Recruiting
Sahlgrenska University Hospital
Gothenburg, Västra Götalands Region, 41345
Sigrun Einarsdottir, MD, PhD, 0046313427358, sigrun.einarsdottir@vgregion.se
Sigrun Einarsdottir, MD, PhD
- Recruiting
Linköping University Hospital
Linköping, Region Östergötaland, 58185
Thomas Erger, MD, 004610-103 00 00, Thomas.Erger@regionostergotland.se
Thomas Erger, MD
- Not yet recruiting
Skåne's University Hospital
Lund, Region Skåne, 22242
Stina Wichert, MD, 004646-17 10 00, Stina.Wichert@skane.se
Stina Wichert, MD
- Not yet recruiting
Karolinska University Hospital
Stockholm, Region Stockholm, 17176
Anna Nordlander, MD, 00468-123 700 00, anna.nordlander@regionstockholm.se
Anna Nordlander, MD
- Recruiting
Uppsala University Hospital
Uppsala, Region Uppsala, 75185
Tobias Tolf, MD, 004618-611 00 00, tobias.tolf@akademiska.se
Tobias Tolf, MD
About this study
Official title: Vaccination Against Human Papillomavirus (HPV) in Women and Men After Stem Cell Transplantation
Patients who undergo allogeneic stem cell transplantation lose previously acquired immunity and are routinely revaccinated against many infectious diseases. For several reasons, these patients have a long-term immune deficiency due to the transplant itself (lack of immune reconstitution) and due to possible complications, primarily GvHD and its treatment. The risk of secondary malignancy in the long-term following an allogeneic bone marrow transplant is greatly increased, and secondary cancer cases account for a significant proportion of late deaths in both women and men after transplantation. Some of these secondary cancers are associated with HPV. The risk of cervical cancer has been reported to be 13 times increased compared to a healthy population.
Therefore in this trial, the aim is to study immune response (antigen-specific antibody response) after vaccination with 9-valent HPV vaccine (Gardasil 9®) in adult women and men (up to and including 45 years of age) who have undergone allogeneic stem cell transplantation. In this trial, the sponsor will compare "early" (start 9 months after tx) with "late" (start 15 months after tx) vaccination.
- Conditions
- Recipients of Allogeneic Stem Cell Transplantation, HPV (Human Papillomavirus)-Associated, Acute Myeloid Leukaemia, Myelodysplastic Syndrome, Diffuse Large B Cell Lymphoma (DLBCL)
- Being tested
- Early start post-transplant vaccination with Gardasil 9®, Late post-transplant vaccination with Gardasil 9®
- Medical subject headings
- Papillomavirus Infections, Leukemia, Myeloid, Acute, Myelodysplastic Syndromes, Lymphoma, Large B-Cell, Diffuse
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Early start post-transplant vaccination with Gardasil 9®Biological
Subjects will receive Gardasil 9® as part of the early post-transplant vaccination, starting at 9 months after transplantation.
Late post-transplant vaccination with Gardasil 9®Biological
Subjects will receive Gardasil 9® as part of the late post-transplant vaccination, starting at 15 months after stem cell transplantation.
| Study group | Role | What they receive |
|---|---|---|
| Late vaccination group | Active comparator | Subjects will receive Gardasil 9® as part of the late post-transplant vaccination, starting at 15 months after stem cell transplantation. Receives: Biological: Late post-transplant vaccination with Gardasil 9® |
| Early vaccination group | Experimental | Subjects will receive Gardasil 9® as part of the early post-transplant vaccination, starting at 9 months after stem cell transplantation. Receives: Biological: Early start post-transplant vaccination with Gardasil 9® |
What is being measured
The primary outcome is the main question the study is designed to answer.
Primary outcome - GMT level against HPV 16
Antibody level (GMT - geometric mean titer) against HPV 16 measured 1 months after the third vaccine dose, early vs late.
Measured: Early group: at month 16 posttransplant. Late group: at month 22 posttransplant.
Secondary outcomes (5)
Secondary outcome 1 - GMT level against all 9 HPV-serotypes
Antibody level (GMT - geometric mean titer) against all 9 HPV-serotypes included in vaccine (-6, -11, -16, -18, -31, -33, -45, -52, -58) measured 1 month after the third vaccine dose. Early vs late.
Measured: Early group: at month 16 posttransplant. Late group: at month 22 posttransplant.
Secondary Outcome 2 - GMT level against all 9 HPV-serotypes
Antibody level (GMT - geometric mean titer) against all 9 HPV-serotypes included in vaccine (-6, -11, -16, -18, -31, -33, -45, -52, -58) measured at 12 months after the third vaccine dose. Early vs late.
Measured: Early group: at month 27 posttransplant. Late group: at month 33 posttransplant.
Secondary Outcome 3 - Proportion seropositive/negative against 9 HPV-serotypes
Proportion seropositive/negative against 9 HPV-serotypes included in vaccine measured 1 and 12 months after third dose. Early vs late.
Measured: Early group: at month 16 and month 27 posttransplant. Late group: at month 22 and month 33 posttransplant.
Secondary Outcome 4 - Seroconversion against 9 HPV-serotypes
Seroconversion against 9 HPV-serotypes included in vaccine, pre-vaccination compared to 1 month after third dose, early vs late.
Measured: Early group: at month 16 posttransplant. Late group: at month 22 posttransplant.
Secondary Outcome 5 - Proportion seropositive against 7/9 HPV-types
Proportion seropositive against 7/9 HPV-types included in the vaccine at 1 and 12 months after completion of vaccination. Early vs late.
Measured: Early group: at month 16 and month 27 posttransplant. Late group: at month 22 and month 33 posttransplant.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted27 Jan 2025
- Study start12 May 2025
- Primary completion31 Oct 2029 (estimated)
- Study completion31 Oct 2029 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Recipients of Allogeneic Stem Cell TransplantationStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 100 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Vastra Gotaland Region
- Sponsor type
- Other government
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06793410
- Sponsor's protocol ID
- ALLO-HPV
- Status last verified
- May 2025
- First submitted
- 13 Jan 2025
- Last updated
- 5 Jun 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: Individual participant data (IPD) from this clinical trial will not be publicly shared to protect participant privacy and confidentiality. However, researchers may contact the Principal Investigator to request access to de-identified data.
Study at a glance
From the registry record, last updated by the sponsor on 5 Jun 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Vaccination Against Human Papillomavirus (HPV) in Women and Men After Stem Cell Transplantation
- ClinicalTrials.gov ID
- NCT06793410
- Acronym / sponsor ID
- ALLO-HPV
- Conditions
- Recipients of Allogeneic Stem Cell Transplantation, HPV (Human Papillomavirus)-Associated, Acute Myeloid Leukaemia, Myelodysplastic Syndrome, Diffuse Large B Cell Lymphoma (DLBCL)
- Phase
- Phase 2
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 100 participants (estimated)
- Lead sponsor
- Vastra Gotaland RegionOther government
- Study start
- 12 May 2025 (actual)
- Primary completion
- 31 Oct 2029 (estimated)
- Study completion
- 31 Oct 2029 (estimated)
- First posted
- 27 Jan 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Patients who undergo allogeneic stem cell transplantation lose previously acquired immunity and are routinely revaccinated against many infectious diseases. For several reasons, these patients have a long-term immune deficiency due to the transplant itself (lack of immune reconstitution) and due to possible complications, primarily GvHD and its treatment. The risk of secondary malignancy in the long-term following an allogeneic bone marrow transplant is greatly increased, and secondary cancer cases account for a significant proportion of late deaths in both women and men after transplantation. Some of these secondary cancers are associated with HPV. The risk of cervical cancer has been reported to be 13 times increased compared to a healthy population.
Therefore in this trial, the aim is to study immune response (antigen-specific antibody response) after vaccination with 9-valent HPV vaccine (Gardasil 9®) in adult women and men (up to and including 45 years of age) who have undergone allogeneic stem cell transplantation. In this trial, the sponsor will compare "early" (start 9 months after tx) with "late" (start 15 months after tx) vaccination.
Study design
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Late vaccination group | Active comparator | Biological: Late post-transplant vaccination with Gardasil 9®Subjects will receive Gardasil 9® as part of the late post-transplant vaccination, starting at 15 months after stem cell transplantation. |
| Early vaccination group | Experimental | Biological: Early start post-transplant vaccination with Gardasil 9®Subjects will receive Gardasil 9® as part of the early post-transplant vaccination, starting at 9 months after stem cell transplantation. |
Who may qualify
- Ages
- 18 to 45 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult
Key inclusion criteria (3 listed)
- Recipient of AlloSCT from related or unrelated donor.
- Adults (men and women) ≥18 years up to and including 45 years of age for vaccination.
- Patients can be included regardless of prior HPV vaccination prior to transplantation
Key exclusion criteria (9 listed)
- Severe thrombocytopenia (under 50 x 10^9) not allowing intramuscular injection
- Severe acute GvHD grade III-IV.
- Extensive chronic GvHD requiring treatment with prednisone doses above 0.7 mg/kg/day plus at least two other systemic treatments against GvHD (for example ruxolitinib or photopheresis).
- Prednisone doses above 1mg/kg/day at study start.
- Treatment with rituximab 6 months before start of vaccination. Doses given later (unusual) do not require exclusion.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Early start post-transplant vaccination with Gardasil 9®Subjects will receive Gardasil 9® as part of the early post-transplant vaccination, starting at 9 months after transplantation. | Biological | Early vaccination group |
| Late post-transplant vaccination with Gardasil 9®Subjects will receive Gardasil 9® as part of the late post-transplant vaccination, starting at 15 months after stem cell transplantation. | Biological | Late vaccination group |
Primary outcome
Primary outcome - GMT level against HPV 16
Time frame: Early group: at month 16 posttransplant. Late group: at month 22 posttransplant.
Antibody level (GMT - geometric mean titer) against HPV 16 measured 1 months after the third vaccine dose, early vs late.
5 secondary outcomes
Secondary outcome 1 - GMT level against all 9 HPV-serotypes
Time frame: Early group: at month 16 posttransplant. Late group: at month 22 posttransplant.
Secondary Outcome 2 - GMT level against all 9 HPV-serotypes
Time frame: Early group: at month 27 posttransplant. Late group: at month 33 posttransplant.
Secondary Outcome 3 - Proportion seropositive/negative against 9 HPV-serotypes
Time frame: Early group: at month 16 and month 27 posttransplant. Late group: at month 22 and month 33 posttransplant.
Secondary Outcome 4 - Seroconversion against 9 HPV-serotypes
Time frame: Early group: at month 16 posttransplant. Late group: at month 22 posttransplant.
Secondary Outcome 5 - Proportion seropositive against 7/9 HPV-types
Time frame: Early group: at month 16 and month 27 posttransplant. Late group: at month 22 and month 33 posttransplant.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 5 Jun 2025.
- Individual participant dataSharing planned: No. Individual participant data (IPD) from this clinical trial will not be publicly shared to protect participant privacy and confidentiality. However, researchers may contact the Principal Investigator to request access to de-identified data.
Related trials for Recipients of Allogeneic Stem Cell Transplantation
Active, not recruitingPhase 2
Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults With Blood Cancers Undergoing Donor Stem Cell Transplant
Acute Biphenotypic Leukemia, Acute Leukemia
RecruitingEarly Phase 1
Donor Virus-Specific CMV or AdV CTL to Treat CMV or AdV Reactivation or Disease After Solid Organ or HCT
Allogeneic Hematopoietic Stem Cell Transplantation Recipient, Cytomegalovirus
Not yet recruiting
Efficacy and Safety of the CloB2M (Clofarabine Combined With Busulfan and Melphalan) Conditioning Regimen in Allogeneic Hematopoietic Stem Cell Transplantation for Adult Patients With Acute Myeloid Leukemia in First Complete Remission
AML (Acute Myelogenous Leukemia), Allogeneic Hematopoietic Stem Cell Transplantation Recipient
RecruitingPhase 2/3
VABu Conditioning in Elderly AML HSCT
Allogeneic Hematopoietic Stem Cell Transplantation Recipient, Acute Myeloid Leukemia (AML)
Recruiting
Prehabilitation for Patients Diagnosed With Blood Cancer and Treated With Al-logeneic Hematopoietic Stem Cell Transplantation
Allogeneic Hematopoietic Stem Cell Transplantation Recipient
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
5 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 2 study testing Early start post-transplant vaccination with Gardasil 9® and Late post-transplant vaccination with Gardasil 9® in people with Recipients of Allogeneic Stem Cell Transplantation and HPV (Human Papillomavirus)-Associated, run by Vastra Gotaland Region at 5 sites in Sweden.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 5 Jun 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 5 sites in Sweden. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Sigrun Einarsdottir, MD, PhD (0046313427358, sigrun.einarsdottir@vgregion.se), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Primary outcome - GMT level against HPV 16 (time frame: Early group: at month 16 posttransplant. Late group: at month 22 posttransplant.). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 5 Jun 2025; AzTrials last refreshed its copy on 26 Oct 2026.